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1. Introduction
Malignant gliomas are not only the most frequent primary brain tumor in the adult pop‐
ulation,  but  also  the  most  aggressive.  Despite  recent  therapeutic  advances,  they  remain
associated with  high morbidity  and mortality.  determinant  of  key biological  features  of
these tumors, like their response, resistance, and patterns of recurrence when challenged
by standard and new therapeutic options. Glioblastoma multiforme (GBM), the most ag‐
gressive  of  the  astrocytic  neoplasms,  is  characterized  by  both  necrosis  as  well  as  high
rates of endothelial proliferation and neo-vascularization. that generates a high consump‐
tion of oxygen and nutrients, thus leading to local hypoxia. The latter activates a cascade
of  signaling  pathways  leading  to:  1)  angiogenesis,  2)  enhanced  motility/invasion,  3)
changes in metabolism, and 4)  the ability to survive oxidative stress.  This  is  a  dynamic
and multifactorial process whose outcome, either death or survival,  is dependent on the
timing and the rates of each of these processes,  as well  as on the molecular characteris‐
tics of the tumor. Therefore,  hypoxia-induced enhancement of motility/invasion may de‐
termine  the  outcome  and  response  to  therapy  of  a  particular  GBM.  We  seek  a  better
understanding of  the  molecular  and phenotypic  effects  of  local  hypoxia  in  GBM.  Here,
we review the definition of hypoxia and its  molecular and phenotypic effects on cancer
cells in general and then turn our attention to its impact on malignant glioma cells.  We
also  examine  the  interplay  between  anti-angiogenesis,  survival,  and  enhanced  motility,
and explore  potential  therapeutic  implications.  We close  with unresolved questions  and
potential future directions.
© 2013 Province et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2. Malignant gliomas
2.1. Overview of gliomas
Central nervous system (CNS) neoplasms are a diverse group that varies widely in terms of
clinical presentation, aggressiveness, and response to therapy, with distinctions in histology
and cellular composition being largely responsible for these differences (Brat and Mapstone
2003). Of the many different types of brain tumors, gliomas are the most frequent primary
brain tumors in adults (Ricard, Idbaih et al. 2012). Lower grade tumors, such as grades I and
II, are commonly well-differentiated with limited amounts of increased cell density and oth‐
er abnormalities. Grade III astrocytomas are anaplastic and have increased vessel and cell
density, cellular atypia, and increased mitotic activity. GBM, grade IV, is characterized by
the presence of necrosis and endothelial proliferation (Brat and Mapstone 2003; Westphal
and Lamszus 2011).
2.2. Significance of malignant gliomas
The annual incidence of malignant gliomas is approximately 4 to 5 per 100 thousand and
this group accounts for approximately 70% of the total number of new cases of malignant
primary brain tumors diagnosed in the United States each year (Wen and Kesari 2008; Wen,
Macdonald et al. 2010). The overall incidence of gliomas is higher among males as compared
to females (7.2 per 100,000 persons-years in males versus 5.0 per 100,000-person years in fe‐
males) and it is also highest among Caucasians, as compared to other ethnic groups (Peak
and Levin 2010). Malignant gliomas can occur in any age group however the incidence in‐
creases in the fifth decade of life and peaks at about 65 years of age (Brat and Mapstone
2003). GBM is the most aggressive glioma. Stupp and colleagues reported that patients treat‐
ed with concomitant and adjuvant Temozolomide and radiotherapy had overall survival
(OS) rates of 27.2 and 9.8 percent at 2 and 5 years, respectively (Stupp, Mason et al. 2005;
Stupp, Hegi et al. 2009).
3. Hypoxia
3.1. Definition of hypoxia
Oxygen plays a central role in cell biology and human cells require constant and adequate
supply of oxygen. Oxygen functions as the terminal electron acceptor in the process of mito‐
chondrial respiration, the process by which ATP is generated for use in most biochemical
reactions (Semenza 2012; Semenza 2012). Hypoxia is a term used to describe reduced levels
of oxygen and can be defined as a condition in which the oxygen pressure in the environ‐
ment is less than 5 to 10 mmHg (Lu and Kang 2010). Hypoxia typically ranges from 0.1 per‐
cent to 3 percent oxygen, with exact definitions varying according to individual researchers
(Wang, Jiang et al. 1995; Semenza 1998; Ke and Costa 2006; Palazon, Aragones et al. 2012).
Normoxia for tissue culture experiments is considered approximately 21 percent oxygen. to
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meet consumption. For example, a local environment including a large number of metabol‐
ically active cancer cells may be hypoxic when the oxygen supply is not enhanced; to pre‐
vent hypoxia, supply must be increased. Factors that contribute to hypoxia include low
partial pressure of oxygen in the blood, reduced ability of blood to carry oxygen, reduced
tissue perfusion, increased diffusion distances, or inability of cells to use oxygen (Hockel
and Vaupel 2001). Hypoxia is threatening to the normal cellular environment and a series of
highly regulated and coordinated response-mechanisms are necessary in order for cells to
survive in hypoxic environments (Wheaton and Chandel 2011).
3.2. Hypoxia and tumor cells
One of the characteristics of cancer cells is deregulated, high cellular proliferation that ulti‐
mately results in structurally and functionally abnormal blood vessels that are unable to
provide an adequate amount of oxygen to meet the increased metabolic demands of prolif‐
eration, which ultimately results in hypoxia (Vaupel, Kallinowski et al. 1989; Harris 2002;
Semenza 2012). Although indirect evidence for hypoxia in human tumors was first reported
in the 1950s, Peter Vaupel and colleagues were among the first researchers to demonstrate
direct evidence of hypoxia in human cancers, as well as linking hypoxia with increased
metastasis and poor prognosis in patients with squamous tumors of the head and neck, cer‐
vical cancers, and breast cancers (Thomlinson and Gray 1955; Hockel, Schlenger et al. 1999;
Hockel and Vaupel 2001; Harris 2002).
Tumor cells generally respond to hypoxia in 1 of 2 ways: either cellular proliferation is re‐
stricted and apoptosis and necrosis may occur or the tumor cells adapt to the stress of the
hypoxic environment and become more aggressive (Vaupel 2008). This adaptation towards
a more aggressive phenotype is accomplished by regulating the expression of various genes
that have critical roles in cellular events, which include cellular proliferation, differentiation,
tumor glycolysis, angiogenesis, and metastasis and invasion (Vaupel 2004; Lu and Kang
2010; Semenza 2012). Additionally, tumor cells not only acquire more invasive and metastat‐
ic properties in response to hypoxia, but also become more resistant to standard treatments,
such as chemotherapies and radiation therapies (Semenza 2012). Hypoxia-associated resist‐
ance to radiation therapy can occur when the partial pressure of oxygen in a tumor is less
than 25-30 mmHg. The mechanism of this resistance is thought to be multi-factorial, howev‐
er some proposed possibilities include decreased oxygen concentrations, higher levels of
heat shock proteins, and the presence of cells with decreased apoptotic potential (Hockel
and Vaupel 2001). Hypoxia-induced resistance to chemotherapy is likely affected by inhibi‐
tion of cellular proliferation, decreased effectiveness of some agents in the setting of hypo‐
xia, tissue acidosis, and/or the loss of apoptotic potential of cells (Hockel and Vaupel 2001).
4. Molecular signals of hypoxia
Hypoxia-inducible factor (HIF) is a transcription factor that plays a critical a central role in
mediating the ability to adapt to low-oxygen concentrations (Wang, Jiang et al. 1995; Semen‐
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za 1998). One of the primary cellular events in response to the initial exposure to hypoxia is
activation of hypoxia-inducible factor 1 (HIF-1), a hetero-dimeric basic helix-loop-helix pro‐
tein, composed of 2 subunits: HIF-1α, which is up-regulated in an oxygen-dependent man‐
ner, and HIF-1β, which is constitutively expressed (Semenza 2000; Lee, Bae et al. 2004; Zhu,
Zhou et al. 2011). Over-expression of HIF-1α is seen in many cancer types associated with a
poor prognosis, like malignancies of the brain, oropharynx, breast, cervix, ovary, and uterus
(Semenza 2003; Lu and Kang 2010).
Hypoxia-inducible factor-2 alpha (HIF-2α) is another mammalian protein that appears to
play  a  role  in  the  cellular  response  to  hypoxia  (Hu,  Wang  et  al.  2003;  Semenza  2012).
HIF-2α  is  structurally  similar  to  HIF-1α,  sharing  48  percent  of  the  overall  amino  acid
identity (Hu, Wang et al. 2003; Ke and Costa 2006). Unlike HIF-1α, which is ubiquitous‐
ly  expressed,  HIF-2α  is  mainly  expressed  in  the  lung,  endothelium,  and  carotid  body
(Kaur,  Khwaja  et  al.  2005;  Ke and Costa  2006).  recently  been discovered;  its  splice  var‐
iants appear to play a role as negative regulators of HIF-1 (Gu, Moran et al. 1998; Maki‐
no,  Cao  et  al.  2001;  Ke  and  Costa  2006).  Other  important  transcription  factors  that  are
activated  by  hypoxia  include  cyclic-AMP-response  element-binding  protein  (CREB),  nu‐
clear  factor-κB  (NF-κB),  activating  protein-1  (AP-1),  and  metal-responsive  transcription
factor-1 (MTF-1) (Harris 2002; Vaupel 2004).
4.1. Mechanisms of hypoxia-induced signaling
Under normal oxygen conditions, HIF-1α is hydroxylated by prolyl hydroxylase (PHD).
This hydroxylation leads to the recognition and binding of von Hippel-Lindau (VHL),
which is part of an E3 ubiquitin ligase complex that targets HIF-1α for degradation through
a proteasomal pathway (Wheaton and Chandel 2011; Semenza 2012). hypoxic conditions,
the hydroxylation of the HIF-1α subunit by PHD is inhibited and, therefore, HIF-1α is stabi‐
lized, resulting in its translocation to the cell nucleus where it dimerizes with the HIF-1β
subunit and forms the active HIF-1. Activation of HIF-1 subsequently results in the recruit‐
ment of transcriptional co-activators and this complex then binds to consensus hypoxia-re‐
sponsive elements (HREs) within the promoter regions of target genes and initiates the
transcription of a variety of hypoxia-responsive genes (Vaupel 2004). These genes can be
grouped into 4 functional categories (see Figure), namely, survival/proliferation, metabo‐
lism, angiogenesis, and invasion/metastasis (Lu and Kang 2010).
4.2. Effects on cell proliferation and survival
Increased rates of cell proliferation and decreased rates of cell death are 2 of the defining dif‐
ferences between neoplastic cells and normal cells. HIF-1 plays an important role in cellular
proliferation. Iyer et al. demonstrated that cells deficient in HIF-1α have reduced rates of cel‐
lular proliferation as compared to wild-type cells under both normoxic and hypoxic condi‐
tions, with the degree of reduction worsened in hypoxia (Iyer, Kotch et al. 1998; Feldser,
Agani et al. 1999). Additionally, several growth factors that contribute to increased cell pro‐
liferation are also HIF-1 target genes. insulin-like growth factor-2 (IGF2) and transforming-
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growth factor-alpha (TGF-α) (Feldser, Agani et al. 1999; Krishnamachary, Berg-Dixon et al.
2003). Binding of these factors to their receptors, namely insulin-like growth factor recep‐
tor-1 (IGFR1) and epidermal growth-factor receptor (EGFR), respectively, leads to autocrine
signaling, resulting in both increased cell proliferation and survival as well as increased ex‐
pression of HIF-1 (Semenza 2003; Ke and Costa 2006). These autocrine signaling pathways
are necessary for cancer progression (Semenza 2003).
4.3. Effects on metabolism
The uptake of glucose by metastatic cancer cells is markedly increased as compared to non-
cancer cells and under hypoxic conditions cells switch from the oxygen-dependent metabol‐
ic pathway, the tricarboxylic acid (TCA) cycle, to the oxygen-independent pathway,
glycolysis (Dang and Semenza 1999; Ke and Costa 2006). HIF-1 plays an active role in this
metabolic response to hypoxia by up-regulating the expression of glycolytic enzymes, such
as aldolase A, phosphoglycerate kinase 1, and lactate dehydrogenase, that convert glucose
to lactate (Vaupel 2004). HIF-1 also induces the over-expression of glucose transporters,
namely GLUT1 and GLUT3, that facilitate the uptake of glucose by the cells (Chen, Pore et
al. 2001; Ke and Costa 2006; Semenza 2012). While it is well known that HIF-1 stimulates
glycolysis, it has also been demonstrated that it can actively repress mitochondrial function
and oxygen consumption by inducing pyruvate dehydrogenase kinase 1 (PDK1). Papan‐
dreou et al nicely demonstrated that HIF-1-dependent block of oxygen utilization results in
increased oxygen availability and in decreased cell death when total oxygen is limiting (Pa‐
pandreou, Cairns et al. 2006). In a feedback loop, this leads to a shut-down of the formation
of mitochondrial acetyl-CoA and oxidative phosphorylation (OXPHOS), which in turn re‐
duces the generation of mitochondrial Reactive Oxygen Species (ROS) and contributes to the
generation of lactate that can be used to acidify the microenvironment leading to increase
invasion and migration. Additionally, a very elegant study by Guzy et al. (2005 Cell metabo‐
lism) found that functionality of complex III of the mitochondrial electron transport chain
(ETC) is required for the hypoxic stabilization of HIF-1α and HIF-2α and that an increase in
ROS links this complex to HIF-alpha stabilization (Guzy, Hoyos et al. 2005). This important
study linked an oxygen-dependent pathway to the stabilization of HIF-1. Thus, while HIF-1
controls glycolysis and shuts-down OXPHOS, functional mitochondria play a role in the
regulation of HIF-1.
4.4. Effects on angiogenesis
Lee et. al demonstrated that inhibition of HIF-1 activity by either anthracycline chemothera‐
py or acriflavine prevents tumor vascularization in mouse models, thus lending support to
the idea that HIF-1 activity is critical in tumor vascularization (Lee, Qian et al. 2009; Lee,
Zhang et al. 2009; Semenza 2012). Angiogenesis is a complex process by which the vascular
system is formed through growth of new capillaries from pre-existing vessels (Wang, Fei et
al. 2004). In addition, although there is great diversity in the factors and signals that contrib‐
ute to angiogenesis, the chemical signal that appears to play the most critical role in the
process is Vascular Endothelial Growth Factor, or VEGF. VEGF is a pro-angiogenic growth
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factor that is secreted by many cells, including mesenchymal, stromal, and especially tumor
cells. VEGF induces the migration of the endothelial precursor cells to sites of angiogenesis
and is also responsible for the proliferation and differentiation of these cells (Ahluwalia and
Gladson 2010). (Kaur, Khwaja et al. 2005). Interestingly, HIF-1 activates the transcription of
VEGF by binding to the HRE in its promoter region (Forsythe, Jiang et al. 1996; Kaur, Khwa‐
ja et al. 2005). Hypoxia also increases VEGF production by stabilizing its mRNA; this effect
is mediated by the 3’ un-translated region of the mRNA (Onesto, Berra et al. 2004; Kaur,
Khwaja et al. 2005). Moreover, HIF-1 up-regulates the expression of additional key mole‐
cules that induce angiogenesis, including stromal-derived factor 1 (SDF1), placental growth
factor (PGF), platelet-derived growth factor B (PDGFB), and angiopoietin (ANGPT) 1 and 2
(Rey and Semenza 2010; Semenza 2012). These pro-angiogenic genes increase vascular den‐
sity, thus supplying oxygen and nutrients to metabolically demanding tumor cells (Ke and
Costa 2006).
4.5. Effects of hypoxia on tumor invasion and motility
Metastasis is a complex process that consists of a series of highly regulated, rate-limiting
steps  in  which  tumor  cells  gain  more  invasive  properties.  Metastasis  begins  with  a
change  in  tumor  plasticity  in  a  process  called  epithelial-mesenchymal  transition  (EMT).
During this  process there is  a loss of  epithelial  cell  characteristics and a gain of  mesen‐
chymal gene expression. In short, this process is characterized by the down-regulation of
epithelial (E)-cadherin, involved in adherence junctions and endothelial stabilization, and
the up-regulation of mesenchymal (N)-cadherin, which allows cells to become more mo‐
tile (Lu and Kang 2010; van Zijl, Krupitza et al. 2011). the repression of (E)-cadherin (Im‐
ai,  Horiuchi  et  al.  2003;  Krishnamachary,  Zagzag  et  al.  2006;  Yang,  Wu et  al.  2008;  Lu
and Kang 2010).  Next,  tumor cells  begin to disrupt the integrity of  the basement mem‐
brane. This is accomplished via a proteolytic cascade that is put into motion by HIF-1α-
dependent  up-regulation  of  enzymes  such  as  cathepsin  D  (CTSD),  urokinase-type
plasminogen-activator  receptor  (uPAR),  and  matrix  metalloproteinase-2  (MMP2)  (Krish‐
namachary, Berg-Dixon et al. 2003; Lu and Kang 2010). Once the basement membrane is
disrupted, tumor cells eventually penetrate the walls of blood vessels in order to become
circulating tumor cells (CTCs) in a process known as intravasation (Lu and Kang 2010).
(Gupta, Nguyen et al. 2007; Lu and Kang 2010). Hypoxia-induced expression of VEGF al‐
so increases the chance of intravasation through the effects of VEGF on increased micro-
vascular permeability and interstitial  fluid pressure (Sullivan and Graham 2007;  Lu and
Kang 2010).
Motility is also an important concept in the process of metastasis. Once the cell-cell junc‐
tions have been broken down by the down-regulation of (E)-cadherin, the cells are quick‐
ly able to reassemble the actin cytoskeleton into protrusive and invasive structures, such
as lamellipodia and filopodia,  that help them to migrate through the degraded extracel‐
lular matrix (ECM), into the blood vessels, and ultimately to their target location (Fathal‐
lah-Shaykh  2005).  Actin-Related  Protein  2/3  (Arp2/3),  which  is  composed  of  2  actin
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related proteins and 5 structural subunits, is controlled by the Scar/WAVE complex, also
known as the WANP complex,  and is essential  to the rapid assembly of actin networks
that  make up lamellipodia (Machesky 2008).  Additionally,  the up-regulation of  the cap‐
ping protein increases the protrusion activity of invasive tumor cells (Yamaguchi, Wyck‐
off  et  al.  2005).  The  formation  of  filopodia  is  controlled  by  proteins  such  as  fascin,
diaphanous, and Mena/VASP (Machesky 2008).
5. Hypoxia and malignant gliomas
5.1. HIF in gliomas
In addition to decreased oxygen tension in brain and GBM tissues, the expression of HIF
in gliomas can be affected by the activation of oncogenes, namely epidermal growth fac‐
tor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR), and/or the loss
of  tumor  suppressor  function  through  p53  and  phosphatase  and  tensin  homolog  gene
(PTEN)  (Brat and Mapstone 2003; Kaur, Khwaja et al. 2005). EGFR affects the expression
of HIF by activating a series  of  pathways,  the first  of  which is  the Phosphatidylinositol
3-kinases  (PI(3)K)  pathway,  which  ultimately  leads  to  increased  HIF-1α  protein  levels
(Clarke,  Smith et  al.  2001;  Kaur,  Khwaja et  al.  2005).  EGFR amplification found in glio‐
blastoma, as well as among other tumors, is also associated with a poor prognosis (Fred‐
erick, Wang et al. 2000; Kaur, Khwaja et al. 2005). Platelet-derived growth factor (PDGF)
has 3  isoforms and 2 receptors and of  these,  the PDGFA isoform and the PDFGR-α re‐
ceptor  are  over-expressed  by  glial  tumor  cells  (Brat  and  Mapstone  2003).  Furthermore,
PDGF is thought to enhance the transcription and secretion of VEGF (Brat and Mapstone
2003).  The  PTEN  gene,  located  on  chromosome  10,  is  a  tumor  suppressor  gene  that  is
mutated in 20 to 40 percent of glioblastoma (Li,  Yen et al.  1997; Cantley and Neel 1999;
Brat and Mapstone 2003; Kaur, Khwaja et al. 2005). Loss of function of the PTEN gene in
gliomas is associated with increased HIF-1α expression as well  as tumor vascularization
and Zundel et al.  showed that over-expression of the gene in gliomas is associated with
reduction in HIF-1α expression (Zundel, Schindler et al.  2000; Kaur, Khwaja et al.  2005).
The p53 gene, mutated in approximately 50% of gliomas and believed to be the ”guardi‐
an of the genome,” exerts a key role in hypoxia by enhancing the degradation of HIF-1α,
by  promoting  the  interaction  of  the  latter  with  MDM2,  which  enhances  ubiquitination
(Hollstein,  Sidransky  et  al.  1991).  Thus,  expression  of  wild-type  p53  down-regulates
VEGF and therefore leads to inhibition of angiogenesis (Brat and Mapstone 2003; Hunter,
Brat  et  al.  2003;  Kaur,  Khwaja et  al.  2005).  Interestingly,  HIF-1α stabilizes p53 by direct
physical interaction. p53 activity is lost in gliomas by multiple mechanisms; mutations of
p53 are common in gliomas (Brat and Mapstone 2003; Kaur, Khwaja et al. 2005). In addi‐
tion,  the MDM2 protein,  which enhances p53 degradation by ubiquitination,  is  over-ex‐
pressed in gliomas (Reifenberger, Liu et al. 1993; Brat and Mapstone 2003). Furthermore,
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loss of p14ARF function in gliomas leads to MDM2-mediated enhanced degradation of p53
(Nakamura, Watanabe et al. 2001; Brat and Mapstone 2003).
5.2. Hypoxia, angiogenesis, and GBM
GBM are highly cellular astrocytic neoplasms; they are histologically characterized by an
area  of  central  necrosis  surrounded by  a  highly  cellular  rim of  viable  tumor  (Brat  and
Mapstone 2003; Giese, Bjerkvig et al. 2003). GBM also display areas of microvascular hy‐
perplasia as well as areas of necrosis with the appearance of tumor cells pseudo-palisad‐
ing around the necrotic centers.  The areas of microvascular hyperplasia are examples of
accelerated  angiogenesis  and are  thought  to  influence  the  biological  behavior  of  malig‐
nant gliomas by favoring aggressive neoplastic growth. angiogenesis in the surrounding
hypoxic  areas.  In  fact,  the  VEGF  concentrations  in  glioblastoma  are  200  to  300  times
greater than serum concentrations (Takano, Yoshii  et  al.  1996;  Brat and Mapstone 2003).
The pseudo-palisading cells have also been shown to over-express HIF-1 and also to se‐
crete  other  pro-angiogenic  factors  in  addition  to  VEGF,  such  as  interleukin  8  (IL-8)
(Rong, Durden et al.  2006; Onishi, Ichikawa et al.  2011). It is also important to note that
newly  formed  blood  vessels  in  malignant  gliomas  generally  have  increased  diameters,
are  highly  permeable,  have  thickened basement  membranes,  and have  highly  prolifera‐
tive endothelial cells (Lopes 2003; Onishi, Ichikawa et al. 2011).
5.3. Hypoxia and invasiveness of GBM
As discussed earlier, cancer cell migration and invasion consists of a series of highly coordi‐
nated steps including dissociation of cellular adhesions, remodeling of the actin cytoskele‐
ton, proteolytic degradation of the ECM, and formation of new adhesions. Brain invasion is
a characteristic feature of malignant gliomas. In vivo studies of glioblastoma have shown
that tumor hypoxia results in increased cell migration (Plasswilm, Tannapfel et al. 2000).
Once again, the pseudopalisading cells found around the necrotic cores in GBM, which up-
regulate HIF-1, appear to be hypoxic and migrating away from the necrotic core (Elstner,
Holtkamp et al. 2007; Onishi, Ichikawa et al. 2011). discovery has revealed that the protein
MINK, which inactivates ADF/cofilin by phosphorylation, is up-regulated in glioma cells as
compared to normal brain cells (Fathallah-Shaykh 2005). Additionally, under hypoxic condi‐
tions, glioblastoma induce the expression of c-Met, which stimulates gliomas cells to secrete
urokinase plasminogen activator (uPA), which converts circulating plasminogen into plas‐
min. The latter helps promote invasion by degrading ECM proteins as well as by activating
matrix metalloproteins, including MMP2, up-regulated in glioma cells (Fathallah-Shaykh
2005; Martens, Schmidt et al. 2006; Eckerich, Zapf et al. 2007; Onishi, Ichikawa et al. 2011).
5.4. Hypoxia and cell survival in GBM
Microarray analysis of cultured glioma cells revealed over-expression of molecules that pro‐
tect them from reactive oxygen species (ROS) and endoplasmic reticulum (ER)-induced
apoptosis (Fathallah-Shaykh 2005). ROS, generated by the rapid multiplication of cancer
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cells, cause a release of cytochrome c leading to apoptosis (Filomeni, Aquilano et al. 2003;
Petrosillo, Ruggiero et al. 2003; Fathallah-Shaykh 2005). Glioma cells appear to acquire pro‐
tective mechanisms against ROS-induced apoptosis. First, by up-regulating protective en‐
zymes such as AKR1A1 and AKR1C1, which belong to the aldo-keto reductase enzyme
super-family (Sanli and Blaber 2001; Fathallah-Shaykh 2005). Second, by up-regulating sev‐
eral antioxidants, some of which include PDG, TALDO1, AFG3L1, ANT2, GSTP1, and
PRDX1 (Berggren, Husbeck et al. 2001; Nonn, Berggren et al. 2003; Fathallah-Shaykh 2005).,
nuclear factor κВ (NF- κВ) has been reported to be constitutively activated in cultured glio‐
ma cells and GBM surgical samples (Bharti and Aggarwal 2002; Robe, Bentires-Alj et al.
2004; Wang, Zhang et al. 2004; Fathallah-Shaykh 2005).
The  ER,  one  of  the  cells  largest  organelles,  is  responsible  for  folding,  glysolating,  and
sorting proteins to their  correct  destinations,  as  well  as  for synthesizing lipids and cho‐
lesterol  components  of  the  cell  membrane.  When  homeostasis  is  disrupted  in  the  ER,
mis-folded  and un-folded  proteins  can  accumulate  with  the  ER lumen,  resulting  in  ER
stress,  which shuts off  protein synthesis leading to apoptosis.  This response is  beneficial
to the cell as a safeguard against carcinogenesis because mis-folded proteins may acquire
aberrant functions. On the other hand, bypassing this response is an important milestone
in  the  development  of  cancer.  Glioma cells  appear  to  acquire  pathways  that  help  them
recover  from ER stress  and avoid  apoptosis.  A normal  ER stress-induced response  ulti‐
mately leads to inactivation of the eukaryotic initiation factor 2 (eIF-2α), which shuts off
protein  synthesis.  By  up-regulating  activating  transcription  factor  4  (ATF4),  malignant
glioma  cells  appear  to  bypass  the  ER  stress-induced  protein  synthesis  inhibition.  ATF4
induces the growth arrest and DNA damage-inducible protein (GADD34), which dephos‐
phorylates eIF2α, causing protein synthesis recovery (Connor, Weiser et al.  2001; Novoa,
Zeng et al. 2001; Brush, Weiser et al. 2003; Fathallah-Shaykh 2005).
6. Linking hypoxia, invasion, and angiogenesis
6.1. Hypoxia, invasion, and angiogenesis in malignant gliomas
Hypoxia, invasion, and angiogenesis are interrelated through a variety of molecular path‐
ways and feedback loops. divide and increase in number, they often out-grow their diffu‐
sion-limited oxygen supplies and hypoxia results. Once the tumor micro-environment
becomes hypoxic, cellular and molecular signaling pathways are initiated in order to pro‐
mote overall tumor survival. These adaptive responses include: 1) increasing cellular resist‐
ance to hypoxia, 2) favoring metabolic pathways that are optimal in hypoxia, 3) increasing
motility and invasive properties in order to seek new oxygen supplies, and 4) initiating an‐
giogenesis in order to create a new vascular supply, or a combination of these responses.
(Shimizu, Eguchi et al. 1995). Therefore, there is evidence that local oxygen concentrations
modulate a switch between proliferative phenotype and an invasive in GBM cells; this is
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called the “Go or Grow” mechanism (Giese, Kluwe et al. 1996; Giese, Loo et al. 1996; Hatzi‐
kirou, Basanta et al. 2012).
When considering angiogenesis as the adaptive mechanism in glial cells, it is necessary to
evaluate the relationship between the rate of angiogenesis and the rate of cellular division. If
cellular division proceeds at a rate faster than angiogenesis, then oxygen supply cannot
meet metabolic demands causing not only local necrosis, but also dissemination of tumor
cells by enhanced brain invasion. On the other hand, if angiogenesis proceeds at a rate faster
than cellular division then oxygen supplies are sufficient to meet metabolic demands and no
necrosis occurs, which is characteristic of anaplastic astrocytoma.
6.2. Anti-angiogenic agents as treatment for malignant gliomas
Both prospective and retrospective clinical trials have shown that Bevacizumab, an anti-an‐
giogenic agent, is effective as a single-agent against recurrent glioblastoma as compared to
historical controls of salvage chemotherapy (Friedman, Prados et al. 2009; Kreisl, Kim et al.
2009; Raizer, Grimm et al. 2010). The Roche-sponsored AVAglio international multicenter
phase III clinical trial, comparing standard of care to standard of care plus Bevacizumab for
the treatment of newly-diagnosed GBM, is completed; the results will be presented at The
Society for Neuro-Oncology 2012 meeting. It is noteworthy that Bevacizumab has a positive
significant impact on progression-free survival times (Norden, Drappatz et al. 2009; van den
Bent, Vogelbaum et al. 2009; Keunen, Johansson et al. 2011).
Interestingly, in vivo GBM models have shown that anti-angiogenic agents enhance tumor
cell migration/invasion. Keunen and colleagues studied a human GBM xenograft model, de‐
rived from patient tumor spheroids, in rats. The results revealed that Bevacizumab induces
vascular remodeling that leads to increased tumor cell invasion into normal brain parenchy‐
ma, associated with a hypoxic tumor microenvironment and a glycolytic metabolism (Keu‐
nen, Johansson et al. 2011). Plasswilm et al. implanted cultured glioma cells in a chicken
embryo model and showed that local hypoxia promotes tumor spread and the development
of secondary tumor cell bulks (Plasswilm, Tannapfel et al. 2000).
6.3. Implications for treatment of malignant gliomas
Treatment with Bevacizumab also has important implications for how tumor progression is
defined. Traditionally, tumor progression has been measured according to the MacDonald
criteria which define progression by increase in contrast enhancement. However, as a result
of blood-brain barrier stabilization secondary to anti-angiogenic agents, contrast enhance‐
ment is no longer a reliable measure of progression. Therefore, the Response Assessment in
Neuro-Oncology (RANO) Working Group developed the RANO criteria as a means to ad‐
dress potential progression by non-enhancing T2/FLAIR (fluid attenuated inversion recov‐
ery) lesions as well as by increases in contrast enhancement in malignant gliomas (Province,
Han et al. 2011). The use of anti-angiogenic agents, namely Bevacizumab, has also raised
many questions about patterns of recurrence in malignant gliomas. Additionally, although
there is some conflicting data on this subject secondary to poor study design and low study
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power, there is evidence that patients who are treated with Bevacizumab exhibit more dif‐
fuse or distant recurrence patterns as compared to those who do not receive Bevacizumab.
Once again, the possibility of more diffuse and distant recurrence patterns may be explained
by the “Go or Grow” mechanism, as explained above, with further supporting evidence de‐
rived from the glioblastoma xenograft model, also detailed above (Keunen, Johansson et al.
2011; Hatzikirou, Basanta et al. 2012).
Hypoxia-mediated enhancement of brain invasion has profound biological and clinical im‐
plications on GBM, in particular in the context of  treatment with anti-angiogenic drugs.
Recall that necrosis is a hallmark of GBM; thus, one can safely assume that, by the time of
the initial clinical presentation, GBM cells have already invaded the surrounding brain pa‐
renchyma because of local hypoxia. This feature of GBM may limit the effectiveness of lo‐
cal  therapeutic  options,  like  radiation  therapy  and  surgical  resection.  Furthermore,  one
could argue that,  though anti-angiogenic  drugs prolong progression free survival  times,
they  may  create  a  more  aggressive  and  invasive  tumor  by  hypoxia-mediated  enhance‐
ment of motility,  which delays clinical progression. These patients may experience a so-
called “honeymoon period,” in which they may appear stable; however, once they recur,
the rate  of  progression of  Bevacizumab-treated tumors may be very acute  secondary to
the large volume of invaded brain. This rationale may explain the limited effects of Beva‐
cizumab on overall survival times.
7. Future directions
The Figure depicts the effects of HIF-1α on key cellular functions. Though some of the sig‐
naling molecules are known, we seem to be only looking at the tip of the iceberg. More re‐
search is needed to fit the pieces of the puzzle. What other molecules are activated by
hypoxia to influence the 4 phenotypes shown in the Figure? How do they relate to HIF-1?
Are there feedback loops between the phenotypes? That is, does motility affect metabolism
and vice versa? We have presented a succinct view of the molecular basis of the four pheno‐
types; however, a detailed analysis is not within the scope of this chapter.
Although preclinical studies have revealed a molecular link between hypoxia, angiogenesis,
and invasion, the clinical implications of these relationships are still not well known and fu‐
ture studies are needed. Drawing from what has already been established regarding the ef‐
fects of anti-angiogenic agents on increased migration and invasion in malignant gliomas, a
plausible direction for future therapeutic development would include blocking not only an‐
giogenesis but also invasion and migration. motility agents in malignant GBM will result in
significant improvement in PFS as well as overall survival times by blocking two of the pri‐
mary mechanisms for their survival.
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8. Conclusion
From this chapter, it is our hope that the reader has gained an understanding of the exten‐
sive role of hypoxia in brain tumors, with specific regard to its role in angiogenesis, inva‐
sion, metabolism, and overall survival of the tumor. Furthermore, although the use of anti-
angiogenic agents as therapeutic options for malignant gliomas has provided some
promising results, it has also revealed the need for further molecular research into the mech‐
anisms for invasion of malignant gliomas, especially as it relates to the hypoxic environ‐
ments created by anti-angiogenic drugs. Hopefully, this combination of efforts to decrease
both angiogenesis and invasion will result in the development of more promising therapeu‐
tic agents to treat this disease.
Figure 1. Cartoon illustrating signaling and degradation of HIF-1α in hypoxia. Under normal oxygen supply, one of the
two proline residues (Pro-402, Pto-564) in HIF-1α is hydroxylated by prolyl hydroxylase. Once hydroxylated HIF-1α is
recognized by VHL, an E3 ubiquitin (Ub) ligase, which targets HIF-1α for degradation through the proteasomal path‐
way. In hypoxic conditions, hydroxylation is inhibited causing the accumulation of HIF-1α, which translocates to nu‐
cleus where it associates with HIF-1β then binds to the HIF responsive Element (HRE) of target genes activating their
transcription. The HIF targeting genes modulate cell survival, metabolism, angiogenesis, and tumor invasion. PGK:
phosphoglycerate kinase, LDH: lactate dehydrogenase.
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